Verlekar, Dattesh <br/><br/>
Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.  [electronic resource] 

 -  Cell death & disease  09 2018 
 - 925 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-4889 
<br/><br/><label>Standard No.: </label>10.1038/s41419-018-0964-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--physiology<br/>Biphenyl Compounds--pharmacology<br/>Caspase 8--metabolism<br/>Caspase Inhibitors--pharmacology<br/>Cell Line<br/>Cell Line, Tumor<br/>Ceramides--metabolism<br/>Drug Resistance, Neoplasm--physiology<br/>HEK293 Cells<br/>Humans<br/>Membrane Proteins--genetics<br/>Nitrophenols--pharmacology<br/>Oligopeptides--pharmacology<br/>Piperazines--pharmacology<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein Binding<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>RNA Interference<br/>RNA, Small Interfering--genetics<br/>Sphingolipids--metabolism<br/>Sphingosine N-Acyltransferase--genetics<br/>Sulfonamides--pharmacology<br/>fas Receptor--metabolism